US EditionKnight Therapeutics is a buy, Stifel says
Summary by Cantech Letter
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Knight Therapeutics is a buy, Stifel says
Knight Therapeutics (Knight Therapeutics Stock Quote, Chart, News, Analysts, Financials TSXV:GUD) is continuing to build momentum, according to Stifel Nicolaus Canada analyst Justin Keywood, who maintained his “Buy” rating and $7.45 target price following the company’s first-quarter earnings release on May 8. Keywood said Knight is steadily assembling a diversified global portfolio of pharmaceutical assets […] Source
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
